Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Rubius Therapeutics Inc (RUBY)

Rubius Therapeutics Inc (RUBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,473
  • Shares Outstanding, K 90,372
  • Annual Sales, $ 0 K
  • Annual Income, $ -196,550 K
  • 60-Month Beta 2.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.69
Trade RUBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.44
  • Most Recent Earnings -0.37 on 11/09/22
  • Next Earnings Date 02/24/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -650.88%)
  • Historical Volatility 220.42%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 836.94% on 05/11/22
  • IV Low 0.00% on 02/07/23
  • Put/Call Vol Ratio 0.14
  • Today's Volume 8
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 574
  • Open Int (30-Day) 558

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +55.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1730 +50.29%
on 01/09/23
0.3400 -23.53%
on 02/06/23
+0.0777 (+42.62%)
since 01/06/23
3-Month
0.1400 +85.71%
on 12/28/22
0.4200 -38.10%
on 12/28/22
-0.0148 (-5.39%)
since 11/07/22
52-Week
0.1400 +85.71%
on 12/28/22
6.5400 -96.02%
on 02/09/22
-5.9900 (-95.84%)
since 02/07/22

Most Recent Stories

More News
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 31.96 (+1.95%)
EVLO : 0.9700 (+6.62%)
FHTX : 8.15 (+0.99%)
MRNA : 171.06 (+0.46%)
OMGA : 6.29 (-6.26%)
RUBY : 0.2600 (-22.89%)
SANA : 4.76 (+0.85%)
MCRB : 5.44 (-0.91%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 31.96 (+1.95%)
EVLO : 0.9700 (+6.62%)
FHTX : 8.15 (+0.99%)
MRNA : 171.06 (+0.46%)
OMGA : 6.29 (-6.26%)
RUBY : 0.2600 (-22.89%)
SANA : 4.76 (+0.85%)
MCRB : 5.44 (-0.91%)
Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?

Rubius Therapeutics, Inc. (RUBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

RUBY : 0.2600 (-22.89%)
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial...

RUBY : 0.2600 (-22.89%)
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.2600 (-22.89%)
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

/PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the...

RUBY : 0.2600 (-22.89%)
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting

Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens...

RUBY : 0.2600 (-22.89%)
Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer

Flagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined...

DNLI : 31.96 (+1.95%)
EVLO : 0.9700 (+6.62%)
FHTX : 8.15 (+0.99%)
MRNA : 171.06 (+0.46%)
OMGA : 6.29 (-6.26%)
RUBY : 0.2600 (-22.89%)
SANA : 4.76 (+0.85%)
MCRB : 5.44 (-0.91%)
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.2600 (-22.89%)
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is...

RUBY : 0.2600 (-22.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 0.3200
2nd Resistance Point 0.3000
1st Resistance Point 0.2800
Last Price 0.2600
1st Support Level 0.2400
2nd Support Level 0.2200
3rd Support Level 0.2000

See More

52-Week High 6.5400
Fibonacci 61.8% 4.0952
Fibonacci 50% 3.3400
Fibonacci 38.2% 2.5848
Last Price 0.2600
52-Week Low 0.1400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar